

# Glenmark to launch blood cancer drug Brukisa in India

The innovative therapy developed by BeOne Medicines, is a Bruton's tyrosine kinase (BTK) inhibitor and is approved in India for the treatment of five distinct B-cell malignancies and globally, the drug is approved in more than 70 countries.



Mumbai: Glenmark Pharmaceuticals is set to launch its licensed cancer drug Zanubrutinib under the brand name Brukisa in India, following approval by the Drugs Controller General of India (DCGI).

The innovative therapy developed by BeOne Medicines, is a Bruton's tyrosine kinase (BTK) inhibitor and is approved in India for the treatment of five distinct B-cell malignancies and globally, the drug is approved in more than 70 countries.

“This launch marks a significant milestone in our innovative oncology portfolio and we look forward to bringing Brukisa to India in the coming months as part of our ongoing partnership with BeiGene (now BeOne Medicines), “said Alok Malik, President and Business Head - India Formulations, Glenmark Pharmaceuticals Ltd.

## News Source:

[https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/glenmark-to-launch-blood-cancer-drug-brukisa-in-india/121725192?utm\\_source=whatsapp\\_web&utm\\_medium=social&utm\\_campaign=socialsharebuttons](https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/glenmark-to-launch-blood-cancer-drug-brukisa-in-india/121725192?utm_source=whatsapp_web&utm_medium=social&utm_campaign=socialsharebuttons)